FierceBiotech· @FierceBiotech · X·· 23 小时前精选AI 评分78
AI 导读
阿斯利康向Summit Therapeutics投资20亿美元，用于加速PD-1xVEGF双特异性抗体ivonescimab与抗体偶联药物（ADC）联用的开发。该投资聚焦于推动这一联合治疗方案的研发进程。
推荐理由
阿斯利康以20亿美元入股Summit，用于推进PD-1xVEGF双抗与ADC联用，读者可据此观察该组合疗法的开发路径。
正文
AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates. https://www.fiercebiotech.com/biotech/astrazeneca-scales-summits-pd-1xvegf-strategy-2b-investment-fuel-adc-combinations
来源：FierceBiotech · x.com